EGFR mutation types and abundance were associated with the overall survival of advanced lung adenocarcinoma patients receiving first-line tyrosine kinase inhibitors

BACKGROUND: Epidermal growth factor receptor tyrosine kinases inhibitors (EGFR-TKIs) are currently recognized as the standard treatment for advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations. Clinically found patients with different EGFR mutational status have different prognos...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yang, Wang, Hongyan, Yang, Sen, Yang, Yuanyuan, Wu, Yufeng, He, Zhen, Ma, Shuxiang, Mo, Yuqing, Chen, Haiyang, Wang, Qiming, Ge, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264099/
https://www.ncbi.nlm.nih.gov/pubmed/35813717
http://dx.doi.org/10.21037/jtd-22-755

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264099/
https://www.ncbi.nlm.nih.gov/pubmed/35813717
http://dx.doi.org/10.21037/jtd-22-755

Ejemplares similares